166 related articles for article (PubMed ID: 23152485)
1. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
Arberas H; Guardo AC; Bargalló ME; Maleno MJ; Calvo M; Blanco JL; García F; Gatell JM; Plana M
J Antimicrob Chemother; 2013 Mar; 68(3):577-86. PubMed ID: 23152485
[TBL] [Abstract][Full Text] [Related]
2. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.
Pozo-Balado MM; Martínez-Bonet M; Rosado I; Ruiz-Mateos E; Méndez-Lagares G; Rodríguez-Méndez MM; Vidal F; Muñoz-Fernández MA; Pacheco YM; Leal M
J Infect Dis; 2014 Sep; 210(6):890-8. PubMed ID: 24652492
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
Cipriani S; Francisci D; Mencarelli A; Renga B; Schiaroli E; D'Amore C; Baldelli F; Fiorucci S
Circulation; 2013 May; 127(21):2114-24. PubMed ID: 23633271
[TBL] [Abstract][Full Text] [Related]
6. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
Rossi R; Lichtner M; De Rosa A; Sauzullo I; Mengoni F; Massetti AP; Mastroianni CM; Vullo V
Clin Exp Immunol; 2011 Nov; 166(2):184-90. PubMed ID: 21985364
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of sodium arsenite during the activation of human CD4+ and CD8+ T lymphocytes.
Tenorio EP; Saavedra R
Int Immunopharmacol; 2005 Dec; 5(13-14):1853-69. PubMed ID: 16275621
[TBL] [Abstract][Full Text] [Related]
9. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.
Latinovic O; Reitz M; Le NM; Foulke JS; Fätkenheuer G; Lehmann C; Redfield RR; Heredia A
Virology; 2011 Mar; 411(1):32-40. PubMed ID: 21232779
[TBL] [Abstract][Full Text] [Related]
10. Immune recovery and T cell subset analysis during effective treatment with maraviroc.
Cossarini F; Galli A; Galli L; Bigoloni A; Salpietro S; Vinci C; Della Torre L; Gianotti N; Spagnuolo V; Lazzarin A; Castagna A; Nozza S
J Antimicrob Chemother; 2012 Oct; 67(10):2474-8. PubMed ID: 22678730
[TBL] [Abstract][Full Text] [Related]
11. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
12. Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.
Lisi L; Tramutola A; De Luca A; Navarra P; Dello Russo C
J Neurochem; 2012 Jan; 120(1):106-14. PubMed ID: 22017448
[TBL] [Abstract][Full Text] [Related]
13. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
[TBL] [Abstract][Full Text] [Related]
14. The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.
Desmetz C; Lin YL; Mettling C; Portalès P; Rabesandratana H; Clot J; Corbeau P
Immunology; 2006 Dec; 119(4):551-61. PubMed ID: 17177831
[TBL] [Abstract][Full Text] [Related]
15. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
Hunt PW; Shulman NS; Hayes TL; Dahl V; Somsouk M; Funderburg NT; McLaughlin B; Landay AL; Adeyemi O; Gilman LE; Clagett B; Rodriguez B; Martin JN; Schacker TW; Shacklett BL; Palmer S; Lederman MM; Deeks SG
Blood; 2013 Jun; 121(23):4635-46. PubMed ID: 23589670
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.
Patro SC; Azzoni L; Joseph J; Fair MG; Sierra-Madero JG; Rassool MS; Sanne I; Montaner LJ
J Leukoc Biol; 2016 Jul; 100(1):223-31. PubMed ID: 26609048
[TBL] [Abstract][Full Text] [Related]
17. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
[TBL] [Abstract][Full Text] [Related]
18. Progesterone-induced inhibition of chemokine receptor expression on peripheral blood mononuclear cells correlates with reduced HIV-1 infectability in vitro.
Vassiliadou N; Tucker L; Anderson DJ
J Immunol; 1999 Jun; 162(12):7510-8. PubMed ID: 10358206
[TBL] [Abstract][Full Text] [Related]
19. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
20. In vitro immunological effects of blocking CCR5 on T cells.
Yuan J; Ren HY; Shi YJ; Liu W
Inflammation; 2015 Apr; 38(2):902-10. PubMed ID: 25380845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
